Search Within

Erica Simone Dayan

  1. "Biostatistics Service"
Formats
  1. Journal Article (3)
  2. Meeting Abstract (3)
Groups
  1. Biostatistics Service (6)
  2. Department of Medicine (6)
  3. Epidemiology and Biostatistics (6)
  4. Genitourinary Oncology Service (6)
  5. Solid Tumor Oncology Division (6)
  6. GME, Medicine (1)

More Groups

People
  1. Howard Scher (6)
  2. Glenn Heller (5)
  3. Michael Morris (4)
  4. Daniel Danila (2)
  5. Karen Autio (2)
  6. Patrick Hilden (2)

More People

Years
  1. 2022 (1)
  2. 2021 (2)
  3. 2018 (1)
  4. 2017 (1)
  5. 2015 (1)
Publications
  1. Journal of Clinical Oncology (3)
  2. European Urology Oncology (1)
  3. European Urology Open Science (1)
  4. Urology (1)
Publishers
  1. American Society of Clinical Oncology (3)
  2. Elsevier BV (2)
  3. Elsevier Science, Inc. (1)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Chromosomal instability (CIN) in circulating tumor cells (CTC) predicts for taxane sensitivity in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Keegan, N. M.; Arfe, A.; Barnett, E.; Cohn, E. D.; Zhao, J.; Carbone, E.; Zanone, M.; Anderson, A.; Wenstrup, R.; Scher, H. I.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Randomized phase 2 trial of abiraterone acetate plus prednisone, degarelix, or the combination in men with biochemically recurrent prostate cancer after radical prostatectomy
    Journal Article

    Autio, K. A.; Antonarakis, E. S.; Mayer, T. M.; Shevrin, D. H.; Stein, M. N.; Vaishampayan, U. N.; Morris, M. J.; Slovin, S. F.; Heath, E. I.; Tagawa, S. T.; more...
    European Urology Open Science (2021)

    Fulltext@MSK | Save
  • Phase 3 randomized controlled trial of androgen deprivation therapy with or without docetaxel in high-risk biochemically recurrent prostate cancer after surgery (TAX3503)
    Journal Article

    Morris, M. J.; Mota, J. M.; Lacuna, K.; Hilden, P.; Gleave, M.; Carducci, M. A.; Saad, F.; Cohn, E. D.; Filipenko, J.; Heller, G.; more...
    European Urology Oncology (2021)

    Fulltext@MSK | Save
  • Phase 2, randomized, 3-arm study of abiraterone acetate and prednisone (AAP), AAP plus degarelix (AAP plus D), and degarelix (D) alone for patients (pts) with biochemically-recurrent prostate cancer (PC) following radical prostatectomy (RP)
    Meeting Abstract

    Autio, K. A.; Antonarakis, E. S.; Mayer, T. M.; Vaishampayan, U. N.; Shevrin, D. H.; Harrison, M. R.; Tagawa, S. T.; Milowsky, M. I.; Graff, J. N.; Beer, T. M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A pilot study of a multimodal treatment paradigm to accelerate drug evaluations in early-stage metastatic prostate cancer
    Journal Article

    O'Shaughnessy, M. J.; McBride, S. M.; Vargas, H. A.; Touijer, K. A.; Morris, M. J.; Danila, D. C.; Laudone, V. P.; Bochner, B. H.; Sheinfeld, J.; Dayan, E. S.; more...
    Urology (2017)

    Fulltext@MSK | Save
  • Efficacy analysis of a phase III study of androgen deprivation therapy (ADT) +/- docetaxel (D) for men with biochemical relapse (BCR) after prostatectomy
    Meeting Abstract

    Morris, M. J.; Hilden, P.; Gleave, M. E.; Armstrong, A. J.; Carducci, M. A.; Saad, F.; Dayan, E. S.; Filipenko, J.; Acosta, I.; Heller, G.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save